Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
| Class:Id | LiteratureReference:2033241 |
|---|
| _displayName | Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice |
|---|
| _timestamp | 2012-01-09 03:51:05 |
|---|
| author | [Person:2033159] Qing, J
[Person:2033093] Du, X
[Person:2033074] Chen, Y
[Person:2033073] Chan, P
[Person:186698] Li, H
[Person:2033223] Wu, Ping
[Person:2033139] Marsters, S
[Person:2033182] Stawicki, S
[Person:2033193] Tien, J
[Person:2033196] Totpal, K
[Person:2033173] Ross, S
[Person:2033187] Stinson, S
[Person:2033091] Dornan, D
[Person:2033099] French, D
[Person:2033214] Wang, QR
[Person:2033184] Stephan, JP
[Person:2033225] Wu, Y
[Person:2033220] Wiesmann, C
[Person:1250148] Ashkenazi, A |
|---|
| created | [InstanceEdit:2033250] Rothfels, K, 2012-01-09 |
|---|
| journal | J Clin Invest |
|---|
| pages | 1216-29 |
|---|
| pubMedIdentifier | 19381019 |
|---|
| title | Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice |
|---|
| volume | 119 |
|---|
| year | 2009 |
|---|
| (literatureReference) | [Pathway:2033515] t(4;14) translocations of FGFR3 [Homo sapiens]
[Reaction:2038386] Dimerization of FGFR3 t(4;14) translocation mutants [Homo sapiens]
[Reaction:2038387] Autocatalytic phosphorylation of FGFR3 t(4;14) translocation mutants [Homo sapiens]
[Reaction:2077420] FGFR3 mutants bind and are inactivated by tyrosine kinase inhibitors [Homo sapiens]
[Reaction:5655262] Activated FGFR3 point, translocation and fusion mutants bind FRS2 [Homo sapiens]
[Reaction:5655268] Activated FGFR2 mutants phosphorylate FRS2 [Homo sapiens]
[Reaction:5655269] Activated FGFR1 mutants bind FRS2 [Homo sapiens]
[Reaction:5655270] Activated FGFR3 point, translocation and fusion mutants phosphorylate FRS2 [Homo sapiens]
[Reaction:5655278] Activated FGFR1 mutants phosphorylate FRS2 [Homo sapiens]
[Reaction:5655284] Activated FGFR4 mutants phosphorylate FRS2 [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice (2033241)
